2022-11-01T11:36:31-05:00 2022-06-30 363963131 MANN WEITZ & ASSOCIATES LLC 111 DEER LAKE ROAD SUITE 125 DEERFIELD IL 60015 990 2021-07-01 366102182 LEUKEMIA RESEARCH FOUNDATION LEUK 8474240600 191 WAUKEGAN ROAD 105 NORTHFIELD IL 60093 KEVIN RADELET EXECUTIVE DIRECTOR 8474240600 2022-11-01 1 KEVIN RADELET 999009999 MARCY STEINDLER P00573131 8472673400 3 AAL1 IAL1 2021 2022-09-23 18:48:47Z KEVIN RADELET 191 WAUKEGAN ROAD 105 NORTHFIELD IL 60093 5452527 0 X WWW.LEUKEMIARF.ORG X 1951 IL THE LEUKEMIA RESEARCH FOUNDATION IS DEDICATED TO CONQUERING ALL BLOOD CANCERS BY FUNDING RESEARCH INTO THEIR CAUSES AND CURES, AND ENRICHING THE QUALITY OF LIFE OF THOSE TOUCHED BY THESE DISEASES. 14 14 8 250 0 0 2574542 2923993 0 0 -16225 -13819 3755 0 2562072 2910174 1550597 1512073 0 0 717325 756120 0 0 303924 204274 232866 2472196 2501059 89876 409115 4522929 5035074 1448622 1582445 3074307 3452629 X DEDICATED TO CONQUERING ALL BLOOD CANCERS BY FUNDING RESEARCH INTO ITS CAUSES AND CURES AND ENRICHING THE QUALITY OF LIFE OF THOSE TOUCHED BY THESE DISEASES. 0 0 1474928 1364595 WE FUND PROMISING RESEARCH WORLDWIDE TO ACCELERATE THE DEVELOPMENT OF NEW TREATMENTS AND THERAPIES FOR ALL BLOOD CANCERS, INCLUDING LEUKEMIA, LYMPHOMA, MYELOMA, AND MYELODYSPLASTIC SYNDROMES. OUR RESEARCHERS' PROJECTS IN GENOMICS, IMMUNOTHERAPIES, AND STEM CELL BIOLOGY HAVE ADVANCED OUR UNDERSTANDING OF WHAT DRIVES THESE CANCERS TO FORM AND PROGRESS AND WHAT BIOLOGICAL MARKERS COULD BE TARGETS FOR TREATMENT. IN FY2022, WE AWARDED THIRTEEN $100,000 GRANTS TO RESEARCHERS WORLDWIDE. IN ADDITION TO SUPPORTING RESEARCH THROUGH OUR NEW INVESTIGATOR RESEARCH GRANT PROGRAM, WE ARE PARTNERING WITH CURES WITHIN REACH THIS YEAR TO FUND A $75,000 DRUG REPURPOSING CLINICAL TRIAL FOR BLOOD CANCERS. THE CLINICAL TRIAL WILL LEVERAGE THE SPEED, SAFETY, AND COST-EFFECTIVENESS OF TESTING A THERAPY ALREADY APPROVED BY THE FDA TO DELIVER A NEW EFFECTIVE TREATMENT TO PATIENTS MORE QUICKLY. 217097 147478 OUR NEED-BASED PATIENT GRANT PROGRAM IS INTENDED TO ASSIST PATIENTS AND THEIR FAMILIES BY EASING THE FINANCIAL BURDEN SO THEY CAN FOCUS ON THEIR HEALTH AND TREATMENT. ELIGIBLE PATIENTS WITH LEUKEMIA, LYMPHOMA, MYELOMA, OR MYELODYSPLASTIC SYNDROME CAN RECEIVE A ONE-TIME GRANT OF UP TO $1,500. IN FY2022, WE DISPERSED GRANTS TO 102 PATIENTS. 256960 THROUGH OUR FREE EDUCATION CONFERENCES AND WEBINARS, PATIENTS AND THEIR LOVED ONES CAN LEARN ABOUT VARIOUS BLOOD CANCER-RELATED TOPICS AND SPEAK WITH EXPERT HEMATOLOGY/ONCOLOGY PHYSICIANS. IN FY2022, APPROXIMATELY 971 PEOPLE REGISTERED FOR OUR EDUCATION PROGRAMS.WE ALSO OFFER FREE PEER SUPPORT SERVICES TO BLOOD CANCER PATIENTS AND CAREGIVERS, INCLUDING AN ONLINE SUPPORT COMMUNITY, AND PARTNER WITH A CANCER SUPPORT ORGANIZATION TO PROVIDE A PEER MENTORING PROGRAM. IN FY2022, MORE THAN 4,000 PEOPLE PARTICIPATED IN OUR PEER SUPPORT PROGRAMS. 1948985 1 1 0 0 0 0 0 0 0 1 1 0 0 1 0 1 1 0 0 0 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 3 0 1 8 1 0 0 0 0 0 0 0 0 0 0 0 0 X 14 14 1 0 0 0 0 0 0 1 1 0 1 1 1 1 1 1 1 1 1 0 0 CA FL GA IL MD MA MI MT NJ NC NY OK TN RI OR UT VA WV WI AK CO CT ME MO OH TX WA MT X X ARLEEN BOUDART 8474240600 191 WAUKEGAN ROAD SUITE 105 NORTHFIELD IL 60093 BLAKE BRANDWEIN PRESIDENT 0.50 X X 0 0 0 GERALD BRIN TREASURER 0.50 X X 0 0 0 PATTY MIX SECRETARY 0.50 X X 0 0 0 ROBERT GRABEMANN GENERAL COUNSEL 0.50 X 0 0 0 HARVEY BRIN AT LARGE MEMBER 0.50 X 0 0 0 MARCIA BRIN AT LARGE MEMBER 0.50 X 0 0 0 JOHN BURKE AT LARGE MEMBER 0.50 X 0 0 0 TODD HOLMES AT LARGE MEMBER 0.50 X 0 0 0 FRANK MARTINEZ AT LARGE MEMBER 0.50 X 0 0 0 LARRY MIX AT LARGE MEMBER 0.50 X 0 0 0 RANDI SCHULLO AT LARGE MEMBER 0.50 X 0 0 0 STEVE WILENSKY AT LARGE MEMBER 0.50 X 0 0 0 SAVYON AMIT AT LARGE MEMBER 0.50 X 0 0 0 RONG CHEN AT LARGE MEMBER 0.50 X 0 0 0 KEVIN RADELET EXECUTIVE DIRECTOR 37.50 X 132087 0 15655 132087 0 15655 1 0 0 0 0 58076 2865917 2923993 6619 6619 2521915 2542353 -20438 -20438 -20438 2910174 0 0 -13819 1068340 1068340 147478 147478 296255 296255 150781 69142 36768 44871 487214 223417 118806 144991 8432 3865 2056 2511 61637 28264 15030 18343 48056 22037 11718 14301 21291 21291 8299 55 3628 4616 728 728 33815 14852 15209 3754 29192 14596 6422 8174 67442 39116 12814 15512 15746 15384 159 203 1125 653 214 258 4059 2354 771 934 FUNDRAISING CAMPAIGNS 29847 29847 MISCELLANEOUS 9932 991 436 8505 MARKETING 6749 6749 PUBLIC RELATIONS 3370 1550 1820 1271 636 280 355 2501059 1948985 248150 303924 511666 1275860 423765 450762 556556 385386 9225 9616 134506 133913 1718 593 2532316 2533606 487683 379251 4522929 5035074 24341 77850 1424281 1504595 1448622 1582445 X 2505927 2992515 568380 460114 3074307 3452629 4522929 5035074 X 409115 15436 -46229 X 0 1 X 1 0 X 2554974 2378441 2598095 2574542 2923993 13030045 2554974 2378441 2598095 2574542 2923993 13030045 723934 12306111 30 7957 22499 14471 6619 51576 237 3755 3992 13085613 0.94040 0.95220 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 85360 305 139 85526 84594 1220 454 85360 83945 1338 689 84594 80000 4636 691 83945 80000 482 482 80000 1.00000 0 0 97696 97428 268 36810 36485 325 593 SECURITY DEPOSIT 4663 BENEFICIAL INTEREST IN TRUST 374588 379251 X 2887571 -75708 8190 44915 -22603 2910174 0 2910174 2509249 8190 8190 2501059 0 2501059 PART V, LINE 4: THE EARNINGS OF THE FUND ARE TO BE USED TO PROVIDE ASSISTANCE TO PATIENTS AND THEIR FAMILIES AND TO FUND MEDICAL RESEARCH. PART X, LINE 2: THE FINANCIAL STATEMENT EFFECTS OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN ARE RECOGNIZED IN THE FINANCIAL STATEMENTS WHEN IT IS MORE LIKELY THAN NOT, BASED ON THE TECHNICAL MERITS, THAT THE POSITION WILL BE SUSTAINED UPON EXAMINATION. AS OF JUNE 30, 2022, THE FOUNDATION HAD NO UNCERTAIN TAX POSITIONS THAT QUALIFY FOR RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS. PART XI, LINE 2D - OTHER ADJUSTMENTS: CANCELLATION OF GRANTS 44,915. 1 EUROPE 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 296255 0 0 0 0 0 0 296255 0 296255 EUROPE NEW INVESTIGATOR RESEARCH GRANT 96255 WIRE TRANSFER 0 EUROPE NEW INVESTIGATOR RESEARCH GRANT 100000 WIRE TRANSFER 0 EUROPE NEW INVESTIGATOR RESEARCH GRANT 100000 WIRE TRANSFER 0 3 0 0 0 0 0 0 0 PART I, LINE 2: THE FINAL SCIENTIFIC REPORT SHOULD BE RECEIVED WITHIN 30 DAYS OF COMPLETION OF THE PROJECT. GRANTEES ARE RQUIRED TO COMPLETE THE FINAL SCIENTIFIC REPORT FORM AND E-MAIL THE FOUNDATION WITH A BRIEF SCIENTIFIC SUMMARY, A BRIEF LAY SUMMARY, AND A LIST OF ANY RESULTING PUBLICATIONS. PART III ACCOUNTING METHOD: 1 UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 SECTION 115 93340 0 NEW INVESTIGATOR RESEARCH GRANT NEW YORK UNIVERSITY GROSSMAN SCHOOL OF MEDICINE ONE PARK AVENUE 6TH FLOOR NEW YORK NY 10016 135562308 501(C)(3) 100000 0 NEW INVESTIGATOR RESEARCH GRANT TEMPLE UNIVERSITY 1801 NORTH BROAD STREET PHILADELPHIA PA 19122 231365971 501(C)(3) 100000 0 NEW INVESTIGATOR RESEARCH GRANT UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 SECTION 115 100000 0 NEW INVESTIGATOR RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL (MASS GENERAL) 55 FRUIT STREET BOSTON MA 02145 041564655 501(C)(3) 100000 0 NEW INVESTIGATOR RESEARCH GRANT WASHINGTON UNIVERSITY IN STLOUIS CAMPUS BOX 1054 ONE BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501(C)(3) 100000 0 NEW INVESTIGATOR RESEARCH GRANT CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BOULEVARD 65-WIL SUITE 1800 LOS ANGELES CA 90048 951644600 501(C)(3) 100000 0 NEW INVESTIGATOR RESEARCH GRANT THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 485 BROADWAY ST REDWOOD CITY CA 94063 411563655 501(C)(3) 100000 0 NEW INVESTIGATOR RESEARCH GRANT BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE OFFICE OF SPONSORED RESEARCH 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 501(C)(3) 100000 0 NEW INVESTIGATOR RESEARCH GRANT UNIVERSITY OF MICHIGAN 3003 S STATE STREET ANN ARBOR MI 48109 386006309 SECTION 115 100000 0 NEW INVESTIGATOR RESEARCH GRANT CURES WITHIN REACH 134 N LASALLE STREET NO 1130 CHICAGO IL 60602 203620169 501(C)(3) 75000 0 BLOOD CANCER CLINICAL TRIAL 11 0 MEDICAL FINANCIAL ASSISTANCE 102 147478 PART I, LINE 2: THE FINAL SCIENTIFIC REPORT SHOULD BE RECEIVED WITHIN 30 DAYS OF COMPLETION OF THE PROJECT. GRANTEES ARE REQUIRED TO COMPLETE THE FINAL SCIENTIFIC REPORT FORM AND E-MAIL THE FOUNDATION WITH A BRIEF SCIENTIFIC SUMMARY, A BRIEF LAY SUMMARY, AND A LIST OF ANY RESULTING PUBLICATIONS. FORM 990, PART VI, SECTION A, LINE 2 HARVEY, MARCIA, AND GERALD BRIN HAVE FAMILY RELATIONSHIPS AND ARE ALSO BOARD MEMBERS. LARRY AND PATTY MIX HAVE FAMILY RELATIONSHIPS AND ARE ALSO BOARD MEMBERS. FORM 990, PART VI, SECTION B, LINE 11B THE FINANCE DIRECTOR AND EXECUTIVE DIRECTOR REVIEW FORM 990. THE FINAL DRAFT OF FORM 990 IS MADE AVAILABLE TO ALL BOARD MEMBERS PRIOR TO FILING. MEMBERS ARE NOTIFIED THAT FORM 990 HAS BEEN POSTED AND THEY CAN ACCESS A URL AND PUT IN THEIR PASSWORD TO VIEW THE DOCUMENT. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS REVIEWED ANNUALLY AND MONITORED AS POTENTIAL REFERENCE AND/OR ACTION IS CALLED FOR. FORM 990, PART VI, SECTION B, LINE 15A THE EXECUTIVE DIRECTOR'S SALARY IS DETERMINED BY A COMPENSATION SURVEY. WE USE A WRITTEN EMPLOYMENT CONTRACT THAT IS APPROVED BY THE BOARD FORM 990, PART VI, SECTION C, LINE 19 WE MAKE OUR GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY AVAILABLE UPON REQUEST. THE FINANCIAL STATEMENTS ARE AVAILABLE ONLINE AND UPON REQUEST. FORM 990, PART XI, LINE 9: CHANGE IN VALUE OF BENEFICIAL INTEREST IN TRUST -91,144. CANCELLATION OF GRANTS 44,915.